Summaries of health policy coverage from major news organizations
Human Genome Sciences Acquires Exclusive Rights To Antibody That Could Be Used in HIV Treatments
Human Genome Sciences on Monday announced that it had acquired exclusive rights to an antibody that could be used in HIV/AIDS treatments, the Baltimore Sun reports. Under the licensing deal, HGS gained exclusive rights to the CCR5 mAb antibody from Abgenix Inc., a California-based pharmaceutical company. CCR5 mAb targets a receptor that if blocked, could prevent HIV from entering the cell. Jill Kiersky, an analyst with Morningstar Inc., said that it is "too early" to determine the impact of the deal on HGS, adding that Phase I trials of drugs have just a 20% chance of success, according to the Sun (Walker, Baltimore Sun, 5/13).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.